It didn’t, for reasons that also reflect the ordinary conditions of how scientific credit circulates. Hollmann’s paper was read by people who read it at the time. Those people then moved on to other things. The chaulmoogra literature continued accumulating citations; the papers that cited Dean’s work continued to exist in the archive. When researchers looked up the history of injectable chaulmoogra treatment in later decades, they were more likely to encounter Dean’s publications — which described the method in chemical and production detail — than Hollmann’s correction, which was a medical paper primarily concerned with clinical outcomes.

 

Credit in science typically attaches to the person who publishes the method, not the person who later states that someone else developed it. The peer-reviewed system is built around original publications, and Ball had none on this topic. Hollmann’s attribution was correct, but it existed as a secondary source, a retrospective claim, rather than as the original paper by the method’s developer.

 

Add to this the dynamics of obscurity that follow when a treatment is superseded. After dapsone became the standard of care for Hansen’s disease in the mid-twentieth century, the entire history of chaulmoogra treatment became less actively referenced in medical education and practice. Researchers who specialized in Hansen’s disease knew the history; practitioners who treated it had less reason to review the pre-dapsone literature in detail. Ball’s name, which had been in Hollmann’s 1922 paper and therefore technically in the archive, was not being actively transmitted to new generations of medical or chemistry students.

ADVERTISEMENT
Advertisement
Share.